CARGO Therapeutics insider option conversion to cash and CVRs in merger
Rhea-AI Filing Summary
CARGO Therapeutics insider option disposition tied to merger. A director reported the disposition of 25,000 stock options with a $4.35 exercise price as part of the company’s merger transaction with Concentra Biosciences. Under the Merger Agreement and related CVR Agreement, outstanding options became vested and were either exercised or converted at the merger into a cash payment equal to the excess of the cash offer over the option exercise price and one non-transferable Contingent Value Right per underlying share; options with exercise prices at or above the cash offer were canceled for no consideration. The filing reflects the contractual settlement mechanics used to convert equity awards into cash and CVRs in connection with the takeover.
Positive
- In-the-money options were cashed out per the Merger Agreement, providing immediate value to optionholders equal to the spread over the exercise price
- CVRs issued for each share underlying converted options, preserving potential contingent upside for former optionholders
Negative
- Options with exercise prices equal to or above the cash offer were canceled for no consideration, which provides no recovery for those optionholders
- Reporting person no longer holds the reported 25,000-option position, reducing insider equity alignment in the successor structure
Insights
TL;DR: Options were cashed out and converted to CVRs under the merger, reflecting standard consideration mechanics in a buyout.
The reported transaction shows typical merger consideration treatment: vested options were converted into a cash amount equal to the spread between the offer price and exercise price, plus a contingent value right per share. This structure preserves immediate cash value for in-the-money optionholders while allocating future contingent upside via CVRs. For deal-sensitive stakeholders, the allocation between cash and CVRs affects realized proceeds and potential future value capture.
TL;DR: Director-level holdings were settled via the merger agreement, reducing insider option exposure post-transaction.
The Form 4 documents a director's option disposition pursuant to the Merger Agreement, which is governance-significant because it alters insider incentive alignment and eliminates those option-based retention levers. The cancellation provision for options with exercise prices at or above the cash amount is notable for equity compensation holders because it results in no payout for certain grants. Disclosure is clear about conversion mechanics and CVR issuance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
Footnotes (1)
- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
